Cysteine protease inhibitors as potential antiparasitic agents

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 8, 2005, Pages 995-1007

  Chung, Joon Yong ^a   Bae, Young An ^b   Na, Byoung Kuk ^b   Kong, Yoon ^b  

^a Inje University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Antiparasitic agent; Cathepsin B; Cathepsin L; Cysteine inhibitor; Non peptide inhibitor; Parasitic disease; Peptidomimetic

Indexed keywords

ANTIPARASITIC AGENT; AZEPAN 3 ONE DERIVATIVE; AZEPINE DERIVATIVE; AZETIDINE DERIVATIVE; BENZENE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CATHEPSIN B; CATHEPSIN B INHIBITOR; CATHEPSIN L; CATHEPSIN L INHIBITOR; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; ESTER DERIVATIVE; HETEROCYCLIC COMPOUND; HYDRAZIDE DERIVATIVE; KETONE DERIVATIVE; NITRILE; OXADIAZOLE DERIVATIVE; PYRROLE DERIVATIVE; PYRROLO[3,2 B]PYRROLE DERIVATIVE; SUCCINIC ACID DERIVATIVE; SULFONAMIDE; SULFONE DERIVATIVE; TETRAHYDROFURAN DERIVATIVE; TETRAHYDROPYRAN DERIVATIVE; THIOKETONE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VINYL DERIVATIVE;

DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME DEGRADATION; ENZYME INHIBITION; HOMEOSTASIS; HOST PARASITE INTERACTION; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; IN VIVO STUDY; METAMORPHOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; NUTRIENT UPTAKE; ORGANOGENESIS; PARASITOSIS; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE DEGENERATION; UNINDEXED SEQUENCE;

EID: 23844556644     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.8.995     Document Type: Review

References (58)

1. BARRETT AJ: Classification of peptidases. Methods Enzymol. (1994) 244:1-15.
2. SAJID M, MCKERROW JH: Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. (2002) 120:1-21.
3. CHUNG YB, KONG Y, YANG HJ, KANG SY, CHO SY: Cysteine protease activities during maturation stages of Paragonimus westermani. J. Parasitol. (1997) 83:902-907.
4. MCKERROW JH: Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol. (1999) 29:833-837.
5. TURK B, TURK D, SALVESEN GS: Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. (2002) 8:1623-1637.
6. BROCKLEHURT K: A sound basis for pH-dependent kinetic studies on enzymes. Protein Eng. (1994) 7:291-299.
7. TURK D, GUNCAR G, PODOBNIK M et al.: Revised definition of substrate binding sites of papain-like cysteine proteases. Biol. Chem. (1998) 379:137-147.
8. GILLMOR SA, CRAIK CS, FLETTERICK RJ: Structural determinants of specificity in the cysteine protease cruzain. Protein Sci. (1997) 6:1603-1611.
9. WARD W, ALVARADO L, RAWLINGS ND, ENGEL JC, FRANKLIN C, McKERROW JH: A primitive enzyme for a primitive cell: the protease required for excystation of Giardia. Cell (1997) 89:437-444.
10. KONG Y, CHUNG YB, CHO SY, KANG SY: Cleavage of immunoglobulin G by excretory-secretory cathepsin S-like protease of Spirometra mansoni plerocercoid. Parasitology (1994) 109:611-621.
11. CHUNG YB, KONG Y, JOO IJ, CHO SY, KANG SY: Excystment of Paragonimus westermani metacercariae by endogenous cysteine protease. J. Parasitol. (1995) 81:137-142.
12. LECAILLE F, KALETA J, BRÖMME D: Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. (2002) 102:4459-4488.
13. KARRER KM, PEIFFER SL, DITOMAS ME: Two distinct gene subfamilies within the family of cysteine protease genes. Proc. Natl. Acad. Sci. USA (1993) 90:3063-3067.
14. LEROY V, THURAIRATNAM S: Cathepsin S inhibitors. Expert Opin. Ther. Patents (2004) 14:301-311.
15. CAI J, JAMIESON C, MOIR J et al.: Cathepsin K inhibitors, 2000 - 2004. Expert Opin. Ther. Patents (2004) 15:33-48.
16. NAGLER DK, SULEA T, MENARD R: Full-length cDNA of human cathepsin F predicts the presence of a cystatin domain at the N-terminus of the cysteine protease zymogen. Biochem. Biophys. Res. Commun. (1999) 257:313-318
17. WEX T, WEX H, BROEMME D: The human cathepsin F gene-α fusion product between an ancestral cathepsin and cystatin gene. Biol. Chem. (1999) 380:1439-1342.
18. KANG TH, YUN DH, LEE EH et al.: A cathepsin F of adult Clonorchis sinensis and its phylogenetic conservation in trematodes. Parasitology (2004) 128:195-207.
19. TURK D, PODOBNIK M, KUHELJ R et al.: Crystal structures of human procathepsin B at 3.2 and 3.3 Å resolution reveal an interaction motif between a papain-like cysteine protease and its peptide. FEBS Lett. (1996) 384:211-214.
20. MUSIL D, ZUCIC D, TURK D et al.: The refined 2.15 Å X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. (1991) 10:2321-2330.
21. QURAISHI O, NAGLER DK, FOX T et al.: The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide. Biochemistry (1999) 38:5017-5023.
22. LIU LX, WELLER PF: Antiparasitic drugs. N. Engl. J. Med. (1996) 334:1178-1184.
23. URBINA JA: Chemotherapy of Chagas' disease. Curr. Pharm. Des. (2002) 8:287-295.
24. CAFFREY CR, SCORY S, STEVERDING D: Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug Targets. (2000) 1:155-62.
25. ROSENTHAL PJ: Protease inhibitors. In: Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery. Humana Press, NJ, USA (2001):325-344.
26. ROSENTHAL PJ, LEE GK, SMITH RE: Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Invest. (1993) 91:1052-1056.
27. SELZER PM, PINGEL S, HSIEH I et al.: Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc. Natl. Acad. Sci. USA. (1999) 96:11015-11022.
28. ENGEL JC, DOYLE PS, HSIEH I et al.: Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. (1998) 188:725-734.
29. ENGEL JC, DOYLE PS, PALMER J et al.: Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J. Cell Sci. (1998) 111:597-606.
30. 2. Exp. Parasitol. (1999) 91:327-333.
31. SEMENOV A, OLSON JE, ROSENTHAL PJ: Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob. Agents Chemother. (1998) 42:2254-2258.
32. 2 recognition subsite: a kinetic and binding energy calculation study. Biochemistry (2005) 44:2781-2789.
33. SANDERSON PE: Small, noncovalent serine protease inhibitors. Med. Res. Rev. (1999) 19:179-197.
34. SHENAI BR, LEE BJ, ALVAREZ-HERNANDEZ A et al.: Structure - activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob. Agents Chemother. (2003) 47:154-160.
35. MCKERROW JH, ENGEL JC, CAFFREY CR: Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. (1999) 7:639-644.
36. ROUSH WR, CHENG J, KNAPP-REED B et al.: Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cystein protease cruzain. Bioorg. Med. Chem. Lett. (2001) 11:2759-2762.
37. GÖTZ MG, CAFFREY CR, HANSELL E et al.: Peptidyl allyl sulfones: a new class of inhibitors for clan CA cysteine proteases. Bioorg. Med. Chem. (2004) 12:5203-5211.
38. HUANG L, LEE A, ELLMAN JA: Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. J. Med. Chem. (2002) 45:676-684.
39. LAKHDAR-GHAZAL F, BLONSKI C, WILLSON M, MICHELS P, PERIE J: Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. Curr. Top. Med. Chem. (2002) 2:439-456.
40. DU X, GUO C, HANSELL E et al.: Synthesis and structure - activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. (2002) 45:2695-2707.
41. CHIBALE K, MUSONDA CC: The synthesis of parasitic cysteine protease and trypanothione reductase inhibitors. Curr. Med. Chem. (2003) 10:1863-1889.
42. CHIYANZU I, HANSELL E, GUT J et al.: Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg. Med. Chem. Lett. (2003) 13:3527-3530.
43. FUJII N, MALLARI JP, HANSELL EJ et al.: Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg. Med. Chem. Lett. (2005) 15:121-123.
44. GREENBAUM DC, MACKEY Z, HANSELL E et al.: Synthesis and structure - activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J. Med. Chem. (2004) 47:3212-3219.
45. DESAI PV, PAYNY A, SABNIS Y et al.: Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J. Med. Chem. (2004) 47:6609-6615.
46. FALGUEYRET JP, OBALLA RM, OKAMOTO O et al.: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J. Med. Chem. (2001) 44:94-104.
47. ROBICHAUD J, BAYLY C, OBALLA R et al.: Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:4291-4295.
48. NO AUTHORS LISTED: Carbamate-based reversible inhibitors of cathepsin S and cathepsin K. Expert Opin. Ther. Patents (2003) 13:1077-1080.
49. HUANG L, ELLMAN JA: General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain. Bioorg. Med. Chem. Lett. (2002) 12:2993-2996.
50. LEUNG D, ABBENANTE G, FAIRLIE DP: Protease inhibitors: current status and future prospects. J. Med. Chem. (2000) 43:305-341.
51. FENWICK AE, GARNIER B, GRIBBLE AD et al.: Solid-phase synthesis of cyclic alkoxyketones, inhibitors of the cysteine protease cathepsin K. Bioorg. Med. Chem. Lett. (2001) 11:195-198.
52. BROEMME D, KALETA J: Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr. Pharm. Des. (2002) 8:1639-1658.
53. MARQUIS RW, RU Y, LOCASTRO SM et al.: Azepanone-based inhibitors of human and rat cathepsin K. J. Med. Chem. (2001) 44:1380-1395.
54. CROFT SL: The current status of antiparasite chemotherapy. Parasitology (1997) 114:S3-S15.
55. COOMBS GH, MOTTRAM JC: Parasite proteinase and amino acid metabolism: possibilities for chemotherapeutic exploitation. Parasitology (1997) 114:S61-S80.
56. ABATH FG: Development of vaccines against human parasitic diseases: tools, current status and perspectives. Expert Opin. Investig. Drugs (2000) 9:301-310.
57. NA BK, KIM TS, ROSENTHAL PJ, LEE JK, KONG Y: Evaluation of cysteine proteases of Plasmodium vivax as antimalarial drug targets: sequence analysis and sensitivity to cysteine protease inhibitors. Parasitol. Res. (2004) 94:312-317.
58. ROSENTHAL PJ: Cysteine proteases of malaria parasites. Int. J. Parasitol. (2004) 34:1489-1499.